• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对比 INFORMS 原始试验数据集中文体肌萎缩型多发性硬化症的临床结果。

A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.

机构信息

Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada/Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.

Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.

出版信息

Mult Scler. 2021 Oct;27(12):1864-1874. doi: 10.1177/1352458520987539. Epub 2021 Jan 19.

DOI:10.1177/1352458520987539
PMID:33464149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8521359/
Abstract

BACKGROUND

The expanded disability status scale (EDSS) is the standard clinical outcome measure in primary progressive multiple sclerosis (PPMS), even though the timed 25-foot walk (T25FW), nine-hole peg test (NHPT) or combinations of these measures may be more useful. The paced auditory serial addition test (PASAT) is a widely used cognitive measure in MS, but little is known about change in PASAT scores over time in PPMS.

OBJECTIVE

The objective of this study is to compare clinical outcome measures in a large PPMS trial data set.

METHODS

We determined significant worsening events on the EDSS, T25FW and NHPT, and PASAT scores over the course of this 3-year trial. We compared unconfirmed, confirmed and sustained disability worsening and contrasted disability worsening with similarly defined improvement. We examined the association of baseline characteristics with the risk of disability worsening at 12, 24 and 36 months with logistic regression models.

RESULTS

The EDSS and T25FW showed most worsening events, while only few patients worsened on the NHPT. Adding the NHPT to a combined outcome added only few further worsening events. PASAT scores slightly increased over time, possibly due to a practice effect.

CONCLUSION

Both the EDSS and T25FW, but not NHPT or PASAT, appear to be useful outcome measures in PPMS.

摘要

背景

扩展残疾状况量表(EDSS)是原发性进展型多发性硬化症(PPMS)的标准临床疗效指标,尽管定时 25 英尺步行(T25FW)、九孔钉测试(NHPT)或这些措施的组合可能更有用。连续听觉加法测试(PASAT)是 MS 中广泛使用的认知测量方法,但关于 PASAT 分数随时间在 PPMS 中的变化知之甚少。

目的

本研究的目的是比较大型 PPMS 试验数据集的临床疗效测量方法。

方法

我们确定了 EDSS、T25FW 和 NHPT 以及 PASAT 评分在这 3 年试验过程中的显著恶化事件。我们比较了未确认、确认和持续的残疾恶化,并将残疾恶化与同样定义的改善进行了对比。我们使用逻辑回归模型检查了基线特征与 12、24 和 36 个月时残疾恶化风险的相关性。

结果

EDSS 和 T25FW 显示出大多数恶化事件,而只有少数患者在 NHPT 上恶化。将 NHPT 添加到综合结果中仅增加了少数进一步的恶化事件。PASAT 分数随着时间的推移略有增加,可能是由于练习效应。

结论

EDSS 和 T25FW 似乎都是 PPMS 的有用疗效指标,但 NHPT 或 PASAT 则不然。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/037f/8521359/27e7463ea42e/10.1177_1352458520987539-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/037f/8521359/097836e8a0d3/10.1177_1352458520987539-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/037f/8521359/27e7463ea42e/10.1177_1352458520987539-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/037f/8521359/097836e8a0d3/10.1177_1352458520987539-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/037f/8521359/27e7463ea42e/10.1177_1352458520987539-fig2.jpg

相似文献

1
A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.对比 INFORMS 原始试验数据集中文体肌萎缩型多发性硬化症的临床结果。
Mult Scler. 2021 Oct;27(12):1864-1874. doi: 10.1177/1352458520987539. Epub 2021 Jan 19.
2
The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. timed 25-foot walk 比 EDSS 更能敏感地反映 PPMS 临床试验的结果:对 PROMISE 临床试验数据集的分析。
J Neurol. 2022 Oct;269(10):5319-5327. doi: 10.1007/s00415-022-11171-2. Epub 2022 May 16.
3
Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.复发缓解型多发性硬化症临床试验结果中扩展残疾状态量表、25英尺计时步行测试和九孔插钉测试的比较
Neurology. 2021 Oct 19;97(16):e1560-e1570. doi: 10.1212/WNL.0000000000012690. Epub 2021 Aug 25.
4
Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis.原发性进行性多发性硬化症患者定时 25 英尺步行和九孔钉测试中显著变化的阈值定义。
Eur J Neurol. 2023 Sep;30(9):2761-2768. doi: 10.1111/ene.15920. Epub 2023 Jun 20.
5
Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.吸烟、肥胖和 PPMS 恶化:对 INFORMS 原始试验数据集的分析。
J Neurol. 2022 Mar;269(3):1663-1669. doi: 10.1007/s00415-021-10750-z. Epub 2021 Aug 15.
6
An enrichment strategy for clinical trials in SPMS.用于 SPMS 临床试验的富集策略。
Mult Scler. 2021 Oct;27(12):1884-1893. doi: 10.1177/1352458520983584. Epub 2021 Jan 6.
7
Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets.多发性硬化症临床试验中的临床结局指标:对 IMPACT 和 ASCEND 原始试验数据集的分析。
Mult Scler. 2020 Oct;26(12):1540-1549. doi: 10.1177/1352458519876701. Epub 2019 Sep 13.
8
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.继发进展型多发性硬化症患者的临床结局和影像学指标对健康相关生活质量的影响。
Mult Scler. 2022 Jul;28(8):1286-1298. doi: 10.1177/13524585211063623. Epub 2021 Dec 30.
9
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.EDSS Plus,一种用于继发进展型多发性硬化症残疾进展的改良终点指标。
Mult Scler. 2017 Jan;23(1):94-105. doi: 10.1177/1352458516638941. Epub 2016 Jul 11.
10
The nine hole peg test as an outcome measure in progressive MS trials.九孔插钉试验作为进行性多发性硬化症试验的一项结果指标。
Mult Scler Relat Disord. 2023 Jan;69:104433. doi: 10.1016/j.msard.2022.104433. Epub 2022 Nov 24.

引用本文的文献

1
Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.测量继发进展型多发性硬化症的认知变化:ASCEND认知子研究分析
J Neurol. 2025 Apr 12;272(5):338. doi: 10.1007/s00415-025-13066-4.
2
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.评估神经营养因子分泌的间充质干细胞在进行性多发性硬化症中的作用。
Mult Scler. 2023 Jan;29(1):92-106. doi: 10.1177/13524585221122156. Epub 2022 Sep 14.
3
The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.

本文引用的文献

1
Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent.颅脑 MRI 钆增强在多发性硬化中具有年龄依赖性。
J Neurol. 2020 Sep;267(9):2619-2624. doi: 10.1007/s00415-020-09895-0. Epub 2020 May 9.
2
Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets.多发性硬化症临床试验中的临床结局指标:对 IMPACT 和 ASCEND 原始试验数据集的分析。
Mult Scler. 2020 Oct;26(12):1540-1549. doi: 10.1177/1352458519876701. Epub 2019 Sep 13.
3
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
timed 25-foot walk 比 EDSS 更能敏感地反映 PPMS 临床试验的结果:对 PROMISE 临床试验数据集的分析。
J Neurol. 2022 Oct;269(10):5319-5327. doi: 10.1007/s00415-022-11171-2. Epub 2022 May 16.
4
Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.复发缓解型多发性硬化症临床试验结果中扩展残疾状态量表、25英尺计时步行测试和九孔插钉测试的比较
Neurology. 2021 Oct 19;97(16):e1560-e1570. doi: 10.1212/WNL.0000000000012690. Epub 2021 Aug 25.
那他珠单抗治疗继发进展型多发性硬化症的疗效(ASCEND):一项开放标签扩展的 3 期、随机、双盲、安慰剂对照试验。
Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.
4
Cognition in multiple sclerosis: State of the field and priorities for the future.多发性硬化症的认知功能:现状与未来重点。
Neurology. 2018 Feb 6;90(6):278-288. doi: 10.1212/WNL.0000000000004977. Epub 2018 Jan 17.
5
Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.进展性多发性硬化症中残疾进展测量指标的比较效用:PROMiSe数据集分析
Neurol Neuroimmunol Neuroinflamm. 2017 May 10;4(4):e358. doi: 10.1212/NXI.0000000000000358. eCollection 2017 Jul.
6
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.25英尺定时步行作为多发性硬化症动态表现结果测量指标的有效性。
Mult Scler. 2017 Apr;23(5):704-710. doi: 10.1177/1352458517690823. Epub 2017 Feb 16.
7
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.符号数字模态测验作为多发性硬化症认知功能结果测量指标的效度
Mult Scler. 2017 Apr;23(5):721-733. doi: 10.1177/1352458517690821. Epub 2017 Feb 16.
8
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.九孔插板测试作为多发性硬化症手部灵巧性的一项性能指标。
Mult Scler. 2017 Apr;23(5):711-720. doi: 10.1177/1352458517690824. Epub 2017 Feb 16.
9
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.奥瑞珠单抗与安慰剂治疗原发性进行性多发性硬化症。
N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.
10
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.原发性进行性多发性硬化症的口服芬戈莫德(INFORMS):一项 3 期、随机、双盲、安慰剂对照试验。
Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28.